ClinicalThought

Share

Program Content

Activities

  • PARPi in Ovarian Cancer
    How I Am Using PARP Inhibitors in the Care of Patients With Ovarian Cancer
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 02, 2019

    Expires: April 30, 2020

  • ASCO 2019 Data on PARPi
    PARP Inhibitors in Recurrent Ovarian Cancer: What’s New at ASCO 2019
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 24, 2019

    Expires: June 22, 2020

  • PARPi Dosing and Safety
    Dosing and Safety of PARP Inhibitors in Ovarian Cancer: Tips From My Clinic
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 27, 2019

    Expires: August 25, 2020

  • QUADRA Trial Implications
    My Thoughts on the Clinical Implications of the Expanded Indication for Niraparib
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 26, 2019

    Expires: November 24, 2020

Faculty

cover img faculity

Laura Alwan, PharmD, BCOP

Clinical Instructor
University of Washington School of Pharmacy
Oncology Clinical Pharmacist
Seattle, Washington

cover img faculity

Robert E. Coleman, MD, FRCP

Professor and Honorary Consultant Medical Oncologist
Cancer Clinical Trials Centre
Academic Unit of Clinical Oncology
Weston Park Hospital
Sheffield, England

cover img faculity

Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Faculty Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Kathleen N. Moore, MD, MS, FASCO

Virginia Kerley Cade Chair in Developmental Therapeutics
Deputy Director, Stephenson Cancer Center at OU Health
Oklahoma City, Oklahoma

Provided by

ProCE Banner

Supporters

Clovis Oncology

Tesaro